Monte Rosa Therapeutics Announced Progress Updates For Its Two Lead Programs, MRT-2359, An MGD Being Developed For MYC-Driven Solid Tumors, And MRT-6160, A VAV1-directed MGD In Development For Systemic And Neurological Autoimmune Diseases
Monte Rosa Therapeutics Announced Progress Updates For Its Two Lead Programs, MRT-2359, An MGD Being Developed For MYC-Driven Solid Tumors, And MRT-6160, A VAV1-directed MGD In Development For Systemic And Neurological Autoimmune Diseases
蒙特羅薩治療公司發佈了兩個主要計劃的進展更新，即MRT-2359和MRT-6160。其中，MRT-2359是針對MYC驅動的實體腫瘤而開發的MDG，而MRT-6160則是針對系統性和神經免疫疾病而開發的VAV1定向MDG。
- Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024.
- IND submission achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; initiation of Phase 1 SAD/MAD study expected this summer with Phase 1 clinical data anticipated in Q1 2025.
- 正在進行的 MRT-2359 針對 MYC 驅動的實體瘤的 1/2 期研究表明，按照 21/7 的時間表給藥 0.5 mg，具有良好的安全性和藥效學特徵；目前正在評估 0.75 mg 劑量水平；最終確定推薦的 2 期劑量，預計將在 2024 年下半年獲得更新的臨床結果。
- MRT-6160 是針對全身和神經系統自身免疫性疾病開發的 VAV1 導向的 MGD，已獲得臨床申請；預計將於今年夏天啓動 1 期 SAD/MAD 研究，1 期臨床數據預計於 2025 年第一季度發佈。